The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis

BACKGROUND: Rituximab has been frequently used as a second-line treatment for patients with immune thrombocytopenia (ITP). The optimal dose and course of rituximab are uncertain. METHODS: A comprehensive search for randomized controlled trials reporting the use of low-dose (100 mg) or standard-dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Yu, Yue, Ming, Hu, Mengjiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514896/
https://www.ncbi.nlm.nih.gov/pubmed/34660807
http://dx.doi.org/10.1155/2021/9992086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514896/
https://www.ncbi.nlm.nih.gov/pubmed/34660807
http://dx.doi.org/10.1155/2021/9992086

Ejemplares similares